Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer

Human Pathology

Volumn 33, Issue 4, 2002, Pages 386-391

  Maeda, Kyoko ^a,b   Tsuda, Hiroshi ^a,b   Hashiguchi, Yasunori ^a,b   Yamamoto, Kumio ^a,b   Inoue, Takeshi ^a,b   Ishiko, Osamu ^a,b   Ogita, Sachio ^a,b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Endometrial cancer; Estrogen receptor methylation; MDM2; p14ARF; p53; p53 pathway

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RNA SPLICING; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0036280276     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.124720     Document Type: Article

References (24)

1. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial cancer
2. Oestorogen and progestin receptors as prognostic indicators in endometrial cancer
3. Mutational analysis of the estrogen-receptor gene in endometrial carcinoma
4. Mutations of the estrogen receptor in endometrial carcinoma: Evidence of an association with high tumor grade
5. Alterations in DNA methylation: A fundamental aspect of neoplasia
6. Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction
7. Estrogen receptor protects p53 from deactivation by human double minute-2
8. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogen
9. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
10. The alternative product from the human CDKN2 locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
11. The p53-binding protein MDM2 gene is differently expressed in human breast carcinoma
12. The role of p16-cyclinD/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma
13. Correlation between the abnormality of G1 pathway and status of estrogen receptor in endometrioid-type endometrial carcinoma
14. Germline p16 mutations in familial melanoma
15. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: Effect on survival
16. Estrogen receptor variants in clinical breast cancer
17. Oestrogen receptor mutants and variants in breast cancer
18. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas
19. p53 overexpression and mutation in endometrial carcinoma: Inverted relation with estrogen and progesterone receptor status
20. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
21. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclinD1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus
22. Distinctive p53 and MDM2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma
23. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma
24. PCR-SSCP: A simple and sensitive method for detection of point mutations in the genomic DNA